Motoko Unoki

Summary

Affiliation: University of Tokyo
Country: Japan

Publications

  1. ncbi Current and potential anticancer drugs targeting members of the UHRF1 complex including epigenetic modifiers
    Motoko Unoki
    Laboratory for Biomarker Development, The Institute of Physical and Chemical Research, Center for Genomic Medicine, RIKEN, Tokyo 108 8639, Japan
    Recent Pat Anticancer Drug Discov 6:116-30. 2011
  2. pmc UHRF1 is a novel diagnostic marker of lung cancer
    M Unoki
    Laboratory for Biomarker, The Institute of Physical and Chemical Research, Center for Genomic Medicine, RIKEN, Tokyo 108 8639, Japan
    Br J Cancer 103:217-22. 2010
  3. pmc UHRF1 is a novel molecular marker for diagnosis and the prognosis of bladder cancer
    M Unoki
    Laboratory for Biomarker Development, The Institute of Physical and Chemical Research, RIKEN, Tokyo, Japan
    Br J Cancer 101:98-105. 2009
  4. doi Drug discovery targeting epigenetic codes: the great potential of UHRF1, which links DNA methylation and histone modifications, as a drug target in cancers and toxoplasmosis
    Motoko Unoki
    Laboratory for Biomarker Development, The Institute of Physical and Chemical Research, Center for Genomic Medicine, RIKEN, 4 6 1 Shirokanedai, Minato ku, Tokyo 108 8639, Japan
    Biochem Pharmacol 78:1279-88. 2009
  5. doi Dysregulation of PRMT1 and PRMT6, Type I arginine methyltransferases, is involved in various types of human cancers
    Masanori Yoshimatsu
    Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, The University of Tokyo, Minato ku, Tokyo, Japan
    Int J Cancer 128:562-73. 2011
  6. doi Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancers
    Shinya Hayami
    Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, The University of Tokyo, Minato ku, Tokyo, Japan
    Int J Cancer 128:574-86. 2011
  7. doi Demethylation of RB regulator MYPT1 by histone demethylase LSD1 promotes cell cycle progression in cancer cells
    Hyun Soo Cho
    Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, The University of Tokyo, Minato ku, Tokyo, Japan
    Cancer Res 71:655-60. 2011
  8. pmc Overexpression of the JmjC histone demethylase KDM5B in human carcinogenesis: involvement in the proliferation of cancer cells through the E2F/RB pathway
    Shinya Hayami
    Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, The University of Tokyo, 4 6 1 Shirokanedai, Minato ku, Tokyo, 108 8639, Japan
    Mol Cancer 9:59. 2010
  9. ncbi ICBP90, an E2F-1 target, recruits HDAC1 and binds to methyl-CpG through its SRA domain
    Motoko Unoki
    Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, The University of Tokyo, 4 6 1 Shiorokanedai, Minato ku, Tokyo 108 8639, Japan
    Oncogene 23:7601-10. 2004
  10. pmc Reviewing the current classification of inhibitor of growth family proteins
    Motoko Unoki
    Laboratory for Biomarker, The Institute of Physical and Chemical Research, RIKEN, Tokyo, Japan
    Cancer Sci 100:1173-9. 2009

Collaborators

Detail Information

Publications11

  1. ncbi Current and potential anticancer drugs targeting members of the UHRF1 complex including epigenetic modifiers
    Motoko Unoki
    Laboratory for Biomarker Development, The Institute of Physical and Chemical Research, Center for Genomic Medicine, RIKEN, Tokyo 108 8639, Japan
    Recent Pat Anticancer Drug Discov 6:116-30. 2011
    ..In this article, the relevant patents on the strategies to develop safer anticancer drugs targeting epigenetic modulators, focusing on members and modifiers of the UHRF1 complex, are discussed...
  2. pmc UHRF1 is a novel diagnostic marker of lung cancer
    M Unoki
    Laboratory for Biomarker, The Institute of Physical and Chemical Research, Center for Genomic Medicine, RIKEN, Tokyo 108 8639, Japan
    Br J Cancer 103:217-22. 2010
    ....
  3. pmc UHRF1 is a novel molecular marker for diagnosis and the prognosis of bladder cancer
    M Unoki
    Laboratory for Biomarker Development, The Institute of Physical and Chemical Research, RIKEN, Tokyo, Japan
    Br J Cancer 101:98-105. 2009
    ..Previous reports have shown that UHRF1 (ubiquitin-like with PHD and ring-finger domains 1) is essential for cellular proliferation. In this study, we examined whether UHRF1 can be a novel molecular marker of bladder cancer...
  4. doi Drug discovery targeting epigenetic codes: the great potential of UHRF1, which links DNA methylation and histone modifications, as a drug target in cancers and toxoplasmosis
    Motoko Unoki
    Laboratory for Biomarker Development, The Institute of Physical and Chemical Research, Center for Genomic Medicine, RIKEN, 4 6 1 Shirokanedai, Minato ku, Tokyo 108 8639, Japan
    Biochem Pharmacol 78:1279-88. 2009
    ..In this review, we discuss several possible methods that can inhibit the multiple unique functions of UHRF1, which can be utilized for treating cancers and toxoplasmosis...
  5. doi Dysregulation of PRMT1 and PRMT6, Type I arginine methyltransferases, is involved in various types of human cancers
    Masanori Yoshimatsu
    Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, The University of Tokyo, Minato ku, Tokyo, Japan
    Int J Cancer 128:562-73. 2011
    ..In summary, our results suggest that dysregulation of PRMT1 and PRMT6 can be involved in human carcinogenesis and that these Type I arginine methyltransferases are good therapeutic targets for various types of cancer...
  6. doi Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancers
    Shinya Hayami
    Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, The University of Tokyo, Minato ku, Tokyo, Japan
    Int J Cancer 128:574-86. 2011
    ....
  7. doi Demethylation of RB regulator MYPT1 by histone demethylase LSD1 promotes cell cycle progression in cancer cells
    Hyun Soo Cho
    Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, The University of Tokyo, Minato ku, Tokyo, Japan
    Cancer Res 71:655-60. 2011
    ..Taken together, our results comprise a novel cell cycle regulatory mechanism mediated by methylation/demethylation dynamics, and they reveal the significance of LSD1 overexpression in human carcinogenesis...
  8. pmc Overexpression of the JmjC histone demethylase KDM5B in human carcinogenesis: involvement in the proliferation of cancer cells through the E2F/RB pathway
    Shinya Hayami
    Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, The University of Tokyo, 4 6 1 Shirokanedai, Minato ku, Tokyo, 108 8639, Japan
    Mol Cancer 9:59. 2010
    ..Cell cycle-dependent characteristics of KDM5B were identified by immunofluorescence and FACS...
  9. ncbi ICBP90, an E2F-1 target, recruits HDAC1 and binds to methyl-CpG through its SRA domain
    Motoko Unoki
    Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, The University of Tokyo, 4 6 1 Shiorokanedai, Minato ku, Tokyo 108 8639, Japan
    Oncogene 23:7601-10. 2004
    ..The data reported here suggest that ICBP90 is involved in cell proliferation by way of methylation-mediated regulation of certain genes...
  10. pmc Reviewing the current classification of inhibitor of growth family proteins
    Motoko Unoki
    Laboratory for Biomarker, The Institute of Physical and Chemical Research, RIKEN, Tokyo, Japan
    Cancer Sci 100:1173-9. 2009
    ..In the present article, we briefly review ING history and propose a possible interpretation of discrepancies between past and recent data...
  11. ncbi Methylation at CpG islands in intron 1 of EGR2 confers enhancer-like activity
    Motoko Unoki
    Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, The University of Tokyo, 4 6 1 Shirokanedai, Minato ku, Tokyo 108 8639, Japan
    FEBS Lett 554:67-72. 2003
    ..Moreover, reporter gene experiments revealed that methylated intron 1 had somehow conferred enhancer-like activity. The data imply the existence of a previously unsuspected mechanism of gene expression regulation...